MedTrace Logo

Evaluating NeuroVision's Neural Vision Correction (NVC) Myopia Treatment

NCT00469612 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2018-09-25

Study results available
· View outcomes & findings →

Summary

The purpose of the present study is to carry out a trial to evaluate the clinical efficacy of the NeuroVision Low Myopia Treatment.

The specific questions to be answered are:

1. Is there an improvement in vision following the treatment without bringing about a change in the subject's prescription for glasses?
2. Can any treatment effect be seen at 6 months and 12 months after the termination of the treatment?

Conditions

  • Myopia

Interventions

DEVICE

NeuroVision's NVC treatment for Low Myopia

NeuroVision's NVC vision correction technology is a method in the treatment of low myopia as the technology is directed at specific neuronal interactions at the level of the visual cortex (area responsible for vision in the brain). The subject will be exposed to a set of visual stimulations (pattern with black and white lines) and visual threshold level will be obtained. The subject will look at these patterns on a computer. The treatment will be applied in successive 30-40 minute sessions, administered 2-3 times a week, for a total of 40 sessions. Every 5 sessions, subject's visual performance (visual acuity and CSF) will be tested in order to continuously monitor a subject's progress.

Sponsors & Collaborators

  • Ohio State University

    lead OTHER

Principal Investigators

  • Donald O Mutti, OD, PhD · Ohio State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2009-12-01
Completion
2009-12-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00469612 on ClinicalTrials.gov